Literature DB >> 2586008

Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.

M Plebani1, D Basso, C Fabris, T Meggiato, G Del Favero, M P Panozzo, P Fogar, D Faggian, C Angonese, A Burlina.   

Abstract

Serum TATI (tumor-associated trypsin inhibitor) was measured in 41 control subjects, 30 patients with pancreatic cancer, 53 with chronic pancreatitis, and 47 with extrapancreatic diseases, mainly of gastrointestinal origin. TATI was found to be elevated in some subjects in all groups of patients; patients with chronic pancreatitis studied during an acute exacerbation of the disease had the highest percentage (68%) of pathological values. TATI was found to be correlated with elastase 1, tissue polypeptide antigen, and total and pancreatic isoamylase. A significant relationship was also found between TATI and serum creatinine levels.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2586008     DOI： 10.1007/bf01727004

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


  13 in total

Review 1.  Pancreas cancer. I. Duct adenocarcinoma. A clinical-pathologic study of 380 patients.

Authors:  A Cubilla; P J Fitzgerald
Journal:  Pathol Annu       Date:  1978

2.  Pancreatic secretory trypsin inhibitor from human amniotic fluid and fetal and neonatal urine: concentrations and physicochemical characterization.

Authors:  K L Kolho; M L Huhtala; H Jalanko; I Rauramo; U H Stenman
Journal:  Clin Chim Acta       Date:  1986-04-30       Impact factor: 3.786

Review 3.  Protein inhibitors of proteinases.

Authors:  M Laskowski; I Kato
Journal:  Annu Rev Biochem       Date:  1980       Impact factor: 23.643

4.  Multicenter evaluation of a specific pancreatic isoamylase assay based on a double monoclonal-antibody technique.

Authors:  N W Tietz; A Burlina; W Gerhardt; W Junge; P Malfertheiner; T Murai; M Otte; W Stein; M Gerber; G Klein
Journal:  Clin Chem       Date:  1988-10       Impact factor: 8.327

5.  Elimination of pancreatic secretory trypsin inhibitor from the circulation. A study in man.

Authors:  W H Marks; K Ohlsson
Journal:  Scand J Gastroenterol       Date:  1983-10       Impact factor: 2.423

6.  Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer.

Authors:  M L Huhtala; K Pesonen; N Kalkkinen; U H Stenman
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

7.  A radioimmunoassay for measurement of human pancreatic secretory trypsin inhibitor in different body fluids.

Authors:  A Eddeland; K Ohlsson
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1978-06

8.  Optimized conditions for determining activity concentration of alpha-amylase in serum, with 1,4-alpha-D-4-nitrophenylmaltoheptaoside as substrate.

Authors:  E Rauscher; U Neumann; E Schaich; S von Bülow; A W Wahlefeld
Journal:  Clin Chem       Date:  1985-01       Impact factor: 8.327

9.  Serum pancreatic secretory trypsin inhibitor in pancreatic disease.

Authors:  M Otsuki; T Oka; I Suehiro; Y Okabayashi; A Ohki; H Yuu; S Baba
Journal:  Clin Chim Acta       Date:  1984-09-29       Impact factor: 3.786

10.  Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases.

Authors:  C Haglund; M L Huhtala; H Halila; S Nordling; P J Roberts; T M Scheinin; U H Stenman
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640
View more
  1 in total

1.  Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.

Authors:  P A Pasanen; M Eskelinen; K Partanen; P Pikkarainen; I Penttilä; E Alhava
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.